Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas. Jagadeesh, D., Horwitz, S. M., Bartlett, N. L., Advani, R. H., Jacobsen, E. D., Duvic, M., Gautam, A., Rao, S., Onsum, M., Fanale, M., Kim, Y. H. AMER SOC CLINICAL ONCOLOGY. 2019
View details for Web of Science ID 000487345806305